Halozyme Therapeutics, Inc. Common StockHALO
Closing prices as of Oct 26, 2026Updated once daily after the US close — not a live quote.

$128.48

+11.49% past month

Notable price movement

  • Oct 26, 2026

    $128.01+1.89%

    Comparable listed companies in Biological Products (No Diagnostic Substances) rose 1.60% on average, with all 6 of 6 higher . The company's 1.89% gain came alongside that sector move. Volume was 0.5x its trailing 20-session average, and the session traded in a range of 1.7% of the low .

  • Oct 23, 2026

    $125.63+0.88%

  • Oct 22, 2026

    $124.54-0.23%

  • Oct 21, 2026

    $124.83+0.37%

  • Oct 20, 2026

    $124.37+1.53%

    Comparable listed companies in biological products rose 2.35% on average, with all 6 of the 6 gaining . The company's 1.53% rise came alongside that sector-wide advance and was smaller than the cohort average .

  • Oct 19, 2026

    $122.50+0.54%

    Comparable listed companies in Biological Products rose 1.29% on average, with five of six rising . HALO's 0.54% gain came alongside that sector advance and was smaller than the cohort average .

  • Oct 16, 2026

    $121.84+0.27%

    Comparable listed companies in Biological Products (No Diagnostic Substances) fell 2.64% on average, with 5 of 6 declining . HALO closed up 0.27%, so its move ran against the direction of the comparable companies rather than with them .

Closing prices for HALO. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Recent news

Seeking AlphaOct 13, 2026Seeking Alpha’s Quant Spotlight: Highest and lowest rated healthcare stocks ahead of Q3The Motley FoolSep 2, 2026Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated?Yahoo FinanceAug 14, 2026Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics?Pr NewswireJun 17, 2026The National Police Association Endorses North Carolina's Honoring and Listening to Our Officers (HALO) LawGeekwireMay 22, 2026What’s next for Bungie? Rumored layoffs and end of ‘Destiny 2’ raise questions about studio’s futureBenzingaJan 28, 2026Halozyme Therapeutics Projects Sustained Growth Well Into 2040 - Halozyme Therapeutics (NASDAQ:HALO)

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.

Prices and financial data are historical and provided for research only. Not investment advice.